Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy.

Abstract

Effective treatment of established tumors requires rational multicombination immunotherapy strategies designed to target all functions of the patient immune system and tumor immune microenvironment. While these combinations build on the foundation of successful immune checkpoint blockade antibodies, it is increasingly apparent that successful immunotherapy will also require a cancer vaccine backbone to engage the immune system, thereby ensuring that additional immuno-oncology agents will engage a tumor-specific immune response. This review summarizes ongoing clinical trials built upon the backbone of cancer vaccines and focusing on those clinical trials that utilize multicombination (3+) immuno-oncology agents. We examine combining cancer vaccines with multiple checkpoint blockade antibodies, novel multifunctional molecules, adoptive cell therapy and immune system agonists. These combinations and those yet to enter the clinic represent the future of cancer immunotherapy. With a cancer vaccine backbone, we are confident that current and coming generations of rationally designed multicombination immunotherapy can result in effective therapy of established tumors.

• Authors: Benjamin Wolfson, S Elizabeth Franks, James W Hodge
• Journal: Vaccines (Vaccines (Basel)) Vol. 9 Issue 5 (May 15 2021) ISSN: 2076-393X [Print] Switzerland
• PMID: 34063388 (Publication Type: Journal Article, Review)